Recent Development in Hereditary Cancer Screening and Pharmacogenomic Testing – Current U.S. Clinical Perspective

1st Seminar (7:00-7:40 pm)

Recent advancements in next generation sequencing (NGS) based multi-gene testing panels in hereditary cancer clinical diagnosis

2nd Seminar (7:40-8:20 pm)

Personalizing medication management - Insight into the clinical benefits of implementing pharmacogenomic testing into clinical practice

1st Seminar Abstract:

Approximately 10% of all cancers are associated with hereditary cancer syndromes. Current recommendations for testing are primarily based on family/personal history of cancer. Because of phenotypic variability, etc. some carriers may be missed.
Clinical utility studies to date have largely focused on these high-risk populations, and thus, clinical utility in a broader population has yet to be defined.
To address this, we validated a 30-gene test for 8-hereditary cancers that is offered through a low-cost, easy-access delivery model.
We will report clinical test results from both the U.S. and Asian populations, and evaluate current recommendations provided by the U.S. National Comprehensive Cancer Network (NCCN)

2nd Seminar Abstract:

Pharmacogenomics is the science underlying the impact of specific genetic variants on the metabolism and mechanism of action of different medications.
Physicians can now gain insight into which medications may pose additional risk of toxicity, lack of efficacy, or side effects.
In this seminar, we will -
- Highlight medications that are impacted by pharmacogenomic variants in cardiology, psychiatry, and oncology, with supporting clinical evidence.
- Present patient cases where pharmacogenomic testing may be beneficial in optimizing medication selection and dosing.
- Discuss the services available through OneOme’s unique provider web portal supporting pharmacists and physicians at point-of-prescription

Program